Hyphens Pharma Further Increases Stake in Ardence Pharma

MT Newswires

May 12, 2025

Hyphens Pharma (SGX:1J5) completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.

Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.

In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.

Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.

In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2534296723"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534296723\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534296723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-12 13:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534296723","market":"sg","top_or_hot":-1,"title":"Hyphens Pharma Further Increases Stake in Ardence Pharma","media":"MT Newswires","content":"<html><body><p> Hyphens Pharma (SGX:1J5) completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.</p><p>Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.</p><p>In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.</p><p>Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.</p><p>In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hyphens Pharma Further Increases Stake in Ardence Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHyphens Pharma Further Increases Stake in Ardence Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2025-05-12 13:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hyphens Pharma (SGX:1J5) completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.</p><p>Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.</p><p>In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.</p><p>Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.</p><p>In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"1J5.SI","symbol_name":"凯帆药剂国际有限公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2534296723","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534296723","pubTimestamp":1747028913,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hyphens Pharma  completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"1J5.SI":"凯帆药剂国际有限公司","BK6506":"制药与医学研究概念","BK6079":"制药"},"translate_title":"Hyphens Pharma进一步增持Ardence Pharma股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"1J5.SI":1},"content_text":"Hyphens Pharma (SGX:1J5) completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}